On Apr. 29, 2022, Moderna announced that it had submitted for a variation to the conditional marketing authorization…
On Apr. 28, 2022, Moderna announced that it had submitted a request for emergency use authorization (EUA) for…
On Apr. 21, 2022, CureVac announced preclinical data demonstrating immune responses and protective efficacy of a bivalent second-generation…
On Apr. 19, 2022, Moderna announced new clinical data on its bivalent COVID-19 booster platform including data on…
On Apr. 11, 2022, CureVac and GSK announced that they had entered into a contract with the German…
On Apr. 9, 2022, BioNTech announced it was granted a pandemic preparedness contract by the Federal Republic of…
On Apr. 7, 2022, Moderna and IAVI announced a collaboration to employ mRNA technology to meet the challenge…
On Mar. 30, 2022, CureVac announced that the first participant was dosed in a Phase 1 study of…
On Mar. 29, 2022, Moderna announced that it had received approval from the U.S. Food and Drug Administration…
On Mar. 23, 2022, Moderna announced the finalization of a strategic partnership with the Australian Federal Government to…
On Mar. 23, 2022, Moderna announced positive interim data from the Phase 2/3 KidCOVE study of the Moderna…
On Mar. 21, 2022, Twist Bioscience announced the launch of specific synthetic RNA positive controls for SARS-CoV-2 encapsulated…
On Mar. 17, 2022, Moderna announced that Health Canada had approved the use of Moderna’s mRNA COVID-19 vaccine,…
On Mar. 17, 2022, Moderna announced that it had submitted a request to the U.S. Food and Drug…
On Mar. 15, 2022, Pfizer and BioNTech announced the companies had submitted an application to the U.S. Food…
On Mar. 14, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) announced they had…
On Mar. 11, 2022, the BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine was recommended by CDCï¾’s Advisory Committee on Immunization…
On Mar. 10, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
On Mar. 9, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) announced a clinical…
On Mar. 7, 2022, Moderna announced that with the assistance of the U.S. Government, it had entered into…
On Feb. 24, 2022, BioNTech announced that the Committee for Medicinal Products for Human Use of the European…
On Feb. 23, 2022, Moderna and Thermo Fisher Scientific announced a 15-year strategic collaboration agreement to enable dedicated…
On Feb. 18, 2022, the WHO announced the first six countries that will receive the technology needed to…
On Feb. 16, 2022, Moderna announced that the Therapeutic Goods Administration in Australia had granted provisional registration for…
On Feb. 16, 2022, BioNTech announced it had introduced its approach to establishing scalable vaccine production by developing…
On Feb. 4, 2022, the Advisory Committee on Immunization Practices (ACIP) issued a standard recommendation for use of…
On Jan. 31, 2022, Moderna announced the U.S. Food and Drug Administration (FDA)Â had approved the Biologics License…
On Jan. 27, 2022, Cocrystal Pharma announced that it had selected two investigational novel antiviral drug candidates for…
On Jan. 26, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
On Jan. 26, 2022, an international research team with the Serratus Project announced they had used a supercomputer…